Elutia Inc. (ELUT)
NASDAQ: ELUT · Real-Time Price · USD
2.160
+0.170 (8.54%)
At close: Aug 13, 2025, 4:00 PM
2.160
0.00 (0.00%)
After-hours: Aug 13, 2025, 4:10 PM EDT
Elutia Revenue
Elutia had revenue of $6.03M in the quarter ending March 31, 2025, a decrease of -9.92%. This brings the company's revenue in the last twelve months to $23.71M, down -5.33% year-over-year. In the year 2024, Elutia had annual revenue of $24.38M, down -1.50%.
Revenue (ttm)
$23.71M
Revenue Growth
-5.33%
P/S Ratio
2.75
Revenue / Employee
$464,922
Employees
51
Market Cap
88.81M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
ELUT News
- 13 days ago - Elutia to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025 - GlobeNewsWire
- 13 days ago - Dr. Michelle LeRoux Williams Earns Washington Business Journal's Medical Device Innovator Award - GlobeNewsWire
- 6 weeks ago - New Evidence Supports the Value of Elutia's Antibiotic-Eluting Platform for Implantable Devices - GlobeNewsWire
- 6 weeks ago - Elutia Wins Dual Honors for Innovation and Product Launches at 2025 Medical Device Network Excellence Awards - GlobeNewsWire
- 2 months ago - Elutia Strengthens Drug-Eluting Biomatrix Platform with Peer-Reviewed Publication of Novel EluPro™ Testing Method - GlobeNewsWire
- 3 months ago - Elutia Inc. (ELUT) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales - GlobeNewsWire
- 3 months ago - Elutia Transitions to Direct Distribution of Its Cardiovascular Product Portfolio - GlobeNewsWire